Premium
Eslicarbazepine for focal epilepsy and acute intermittent porphyria ∗
Author(s) -
HerreraFortin Tamara,
Pana Raluca,
Wesolowska Ewa,
BourréTessier Josiane,
Nguyen Dang K.
Publication year - 2020
Publication title -
epileptic disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.673
H-Index - 53
eISSN - 1950-6945
pISSN - 1294-9361
DOI - 10.1684/epd.2020.1171
Subject(s) - porphyria , acute intermittent porphyria , epilepsy , exacerbation , medicine , heme , dermatology , enzyme , psychiatry , chemistry , biochemistry
Porphyrias are rare genetic disorders which cause a deficiency in the enzymes involved in the biosynthesis of heme. The treatment of epilepsy in patients with acute intermittent porphyria can be difficult since many anticonvulsants can increase heme synthesis and trigger porphyric attacks. We report a patient with focal epilepsy successfully treated with eslicarbazepine without exacerbation of porphyria.